[1] Melmed S.Pathogenesis of pituitary tumors[J]. Endocrinology and metabolism clinics of North America, 1999, 28(1):1-12. [2] Piccart M, Hortobagyi G N, Campone M, et al.Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2[J]. Annals of oncology: official journal of the European Society for Medical Oncology, 2014, 12(12):2357-2362. [3] Burstein N, Harold J, Cirrincion E, et al.Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: A randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302(alliance)[J]. Journal of Clinical Oncology, 2014, 35(35):3959-3966. [4] Gao H, Xue Y, Cao L, et al.ESR1 and its antagonist fulvestrant in pituitary adenomas[J]. Mol Cell Endocrinol, 2017, 3(5) :32-41. [5] Heaney A P, Fernando M, Melmed S.Functional role of estrogen in pituitary tumor pathogenesis[J]. J Clin Invest, 2002, 109(2):277-283. [6] Heaney A P, Horwitz G A, Wang Z, et a1.Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis[J]. Nat Med, 1999, 5(11):1317-1321. [7] McCabe C J, Boelaert K, Tannahill L A, et a1.Vascular endothelial growth factor, its receptor KDR/FLK-1, and pituitary tumor transforming gene in pituitary tumors[J]. J Clin Endocfinol Metab, 2002, 87(9):4238-4244. [8] 王丹宁, 赵金波. 氟维司群治疗绝经后激素受体阳性晚期乳腺癌的临床研究进展[J]. 医学信息, 2018, 31(13):4-8. [9] 中华人民共和国卫生部. GB 15193.3-2003急性毒性试验[S]. 北京:中国标准出版社,2003. [10] Bogliolo S, Cassani C, Dominoni M, et al.The role of fulvestrant in endometrial cancer[J].Expert Opin Drug Metab Toxicol, 2017, 13(5):537-544. [11] Liu J, Zheng S, Akerstrom V L, et al.Fulvestrant3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)[J]. J Med Chem, 2016, 59(17):8134-8140. |